Targeting Alpha-Synuclein: Breakthroughs in the Quest to Halt Parkinson's Progression

Unique protein structures could hold the key to treatment for Parkinson's disease

Parkinson's Disease Therapies Targeting Alpha Synuclein

IJMS, Free Full-Text

PDF) Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers, Translational Neurodegeneration

IJMS, Free Full-Text

Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets

The quest for a disease-modifying drug for Parkinson's disease continues - Drug Discovery and Development

Frontiers Parkinson's Disease: A Nanotheranostic Approach Targeting Alpha- Synuclein Aggregation

Pathological Pathways and Alpha-Synuclein in Parkinson's Disease: A View from the Periphery

PDF] The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease

The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic